Plus Therapeutics Files S-1/A Amendment

TL;DR

PLUS filing S-1/A, formerly Cytori. SEC registration update.

AI Summary

Plus Therapeutics, Inc. filed an S-1/A amendment on June 24, 2024, for its registration statement. The company, formerly known as Cytori Therapeutics, Inc. and Macropore Inc., is based in Austin, Texas, and operates in the surgical and medical instruments sector. The filing relates to a securities registration, but specific details on the number of shares or dollar amounts being offered are not provided in this excerpt.

Why It Matters

This filing indicates Plus Therapeutics is actively engaging with the SEC for a securities offering, which could impact its capital structure and future operations.

Risk Assessment

Risk Level: medium — S-1/A filings often precede significant capital raises or changes in a company's structure, which carry inherent market risks.

Key Numbers

• 20240624 — Filing Date (Indicates the amendment was filed on this date.)
• 78756 — ZIP Code (Primary business and mailing address ZIP code.)

Key Players & Entities

• PLUS THERAPEUTICS, INC. (company) — Registrant
• Cytori Therapeutics, Inc. (company) — Former company name
• Macropore Inc (company) — Former company name
• Marc H. Hedrick, M.D. (person) — President and Chief Executive Officer
• 333-280061 (dollar_amount) — SEC File Number

FAQ

Key Financial Figures

• $0 — 4,596 shares of common stock, par value $0.001, of Plus Therapeutics, Inc., a Dela
• $1.79 — sing sale price of our Common Stock was $1.79 per share. Investing in our common st
• $3.0 million — veral cancer targets. We have an active $3.0 million award from U.S. National Institutes of

Filing Documents

• d840996ds1a.htm (S-1/A) — 1481KB
• g840996g01a00.jpg (GRAPHIC) — 43KB
• 0001193125-24-166942.txt ( ) — 1537KB

USE OF PROCEEDS

USE OF PROCEEDS 45 MARKET INFORMATION FOR COMMON STOCK 45 DIVIDEND POLICY 46

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 46

BUSINESS

BUSINESS 58 MANAGEMENT 64

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 71 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 77

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 79

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 82 SELLING STOCKHOLDERS 87 PLAN OF DISTRIBUTION 93 LEGAL MATTERS 96 EXPERTS 96 WHERE YOU CAN FIND ADDITIONAL INFORMATION 96 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING F-19 You should rely only on the information provided in this prospectus, as well as the information incorporated by reference to exhibits to the registration are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date of the applicable document. Since the date of this prospectus and the documents filed as exhibits to the registration statement of which this prospectus forms a part, our business, financial condition, results of operations and prospects may have changed. i Table of Contents ABOUT THIS PROSPECTUS This prospectus relates to the resale by the selling stockholders identified in this prospectus under the section entitled Selling Stockholders , from time to time, of up to an aggregate up to 10,774,596 shares of our common stock, consisting of: (i) 1,439,988 are shares of common stock, (ii) 2,151,544 shares are issuable upon the exercise of Pre-Funded Warrants, (iii) 3,591,532 shares are issuable upon the exercise of Series A Common Stock Warrants, and (iv) 3,591,532 shares are issuable upon the exercise of Series B Common Stock Warrants. We are not selling any shares of common stock under this prospectus, and we will not receive any proceeds from the sale of shares of common stock offered hereby by the selling stockholders, although we may receive cash from the exercise of the Warrants. You should r

View Full Filing

View this S-1/A filing on SEC EDGAR